**ILD**

* American Thoracic Society: [Interstitial Lung Disease Guidelines](https://www.thoracic.org/statements/insterstitial-lung-disease.php)
* Mechanism of Idiopathic Pulmonary Fibrosis: [Emerging Therapies](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815310/)
* American Thoracic Society: [Idiopathic Pulmonary Fibrosis Guidelines 2021](https://www.thoracic.org/education-center/ild/pdf/ats-pocket-guide_2021_redesign_r2.pdf)
* Pirfenidone NEJM: [A Phase 3 Trial of Pirfenidone](https://www.nejm.org/doi/full/10.1056/nejmoa1402582)
* Nintedanib NEJM: [Efficacy and Safety in Idiopathic Pulmonary Fibrosis](https://www.nejm.org/doi/full/10.1056/nejmoa1402584)
* Mycophenolate Mofetil Versus Oral Cyclophosphamide in Scleroderma: [SLS II Trial](https://pubmed.ncbi.nlm.nih.gov/27469583/)